Efficacy of two levofloxacin-containing second-line therapies for Helicobacter pylori: A pilot study

Helicobacter

Volumn 18, Issue 5, 2013, Pages 378-383

  Calhan, Turan ^a   Kahraman, Resul ^a   Sahin, Abdurrahman ^a   Senates, Ebubekir ^b   Doganay, Hamdi Levent ^a   Kanat, Evren ^a   Ozdil, Kamil ^a   Sokmen, Haci Mehmet ^a  

^a Umraniye Training and Research Hospital ^*  (Turkey)

^b GATA HAYDARPASA TRAINING HOSPITAL   (Turkey)

Author keywords

H. pylori eradication; H. pylori re treatment; Levofloxacin; Second line therapy

Indexed keywords

AMOXICILLIN; BISMUTH CITRATE; LEVOFLOXACIN; METRONIDAZOLE; PANTOPRAZOLE; TETRACYCLINE;

ABDOMINAL PAIN; ADULT; APHTHOUS STOMATITIS; ARTICLE; CONSTIPATION; CONTROLLED STUDY; DIARRHEA; DRUG EFFICACY; DRUG TREATMENT FAILURE; ERADICATION THERAPY; FECES ANALYSIS; FEMALE; FLATULENCE; HELICOBACTER INFECTION; HELICOBACTER PYLORI; HUMAN; MAJOR CLINICAL STUDY; MALE; METALLIC TASTE; MYALGIA; NAUSEA; PATIENT COMPLIANCE; PRIORITY JOURNAL; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; RASH; TASTE DISORDER; TREATMENT RESPONSE;

H. PYLORI ERADICATION; H. PYLORI RE-TREATMENT; LEVOFLOXACIN; SECOND-LINE THERAPY;

ADULT; AGED; ANTI-BACTERIAL AGENTS; ANTIGENS, BACTERIAL; DRUG THERAPY, COMBINATION; DRUG TOXICITY; FECES; FEMALE; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HUMANS; MALE; MEDICATION ADHERENCE; MIDDLE AGED; OFLOXACIN; PILOT PROJECTS; TREATMENT OUTCOME; TURKEY; YOUNG ADULT;

EID: 84881605746     PISSN: 10834389     EISSN: 15235378     Source Type: Journal    
DOI: 10.1111/hel.12056     Document Type: Article

References (36)

1. Fock KM, Ang TL. Epidemiology of Helicobacter pylori infection and gastric cancer in Asia. J Gastroenterol Hepatol 2010;25:479-86.
2. Hopkins RJ, Girardi LS, Turney EA. Relationship between Helicobacter pylori eradication and reduced duodenal and gastric ulcer recurrence: a review. Gastroenterology 1996;110:1244-52.
3. Rauws EA, Tytgat GN. Cure of duodenal ulcer associated with eradication of Helicobacter pylori. Lancet 1990;335:1233-5.
4. Marshall BJ, Goodwin CS, Warren JR, Murray R, Blincow ED, Blackbourn SJ, Phillips M, Waters TE, Sanderson CR. Prospective double-blind trial of duodenal ulcer relapse after eradication of Campylobacter pylori. Lancet 1988;2:1437-42.
5. Wong BC, Lam SK, Lai KC, Hu WH, Ching CK, Ho J, Yuen ST, Chan CK, Lau GK, Lai CL. Triple therapy for Helicobacter pylori eradication is more effective than long-term maintenance antisecretory treatment in the prevention of recurrence of duodenal ulcer: a prospective long-term follow-up study. Aliment Pharmacol Ther 1999;13:303-9.
6. Malfertheiner P, Megraud F, O'Morain C, Bazzoli F, El-Omar E, Graham D, Hunt R, Rokkas T, Vakil N, Kuipers EJ. Current concepts in the management of Helicobacter pylori infection: the Maastricht III Consensus Report. Gut 2007;56:772-81.
7. Gisbert JP, Pajares JM. Review article: Helicobacter pylori "rescue" regimen when proton pump inhibitor-based triple therapies fail. Aliment Pharmacol Ther 2002;16:1047-57.
8. Gisbert JP, Pajares JM. Helicobacter pylori "rescue" therapy after failure of two eradication treatments. Helicobacter 2005;10:363-72.
9. Saad RJ, Schoenfeld P, Kim HM, Chey WD. Levofloxacin-based triple therapy versus bismuth-based quadruple therapy for persistent Helicobacter pylori infection: a meta-analysis. Am J Gastroenterol 2006;101:488-96.
10. Gisbert JP, Morena F. Systematic review and meta-analysis: levofloxacin-based rescue regimens after Helicobacter pylori treatment failure. Aliment Pharmacol Ther 2006;23:35-44.
11. Wong WM, Gu Q, Chu KM, Yee YK, Fung FM, Tong TS, Chan AO, Lai KC, Chan CK, Wong BC. Lansoprazole, levofloxacin and amoxicillin triple therapy vs. quadruple therapy as second-line treatment of resistant Helicobacter pylori infection. Aliment Pharmacol Ther 2006;23:421-7.
12. Giannini EG, Bilardi C, Dulbecco P, Mamone M, Santi ML, Testa R, Mansi C, Savarino V. A study of 4- and 7-day triple therapy with rabeprazole, high-dose levofloxacin and tinidazole rescue treatment for Helicobacter pylori eradication. Aliment Pharmacol Ther 2006;23:281-7.
13. Gatta L, Zullo A, Perna F, et al. A 10-day levofloxacin-based triple therapy in patients who have failed two eradication courses. Aliment Pharmacol Ther 2005;22:45-9.
14. Coelho LG, Moretzsohn LD, Vieira WL, et al. New once-daily, highly effective rescue triple therapy after multiple Helicobacter pylori treatment failures: a pilot study. Aliment Pharmacol Ther 2005;21:783-7.
15. Gisbert JP, Castro-Fernández M, Bermejo F, Olivares D, H. pylori Study Group of the Asociación Española de Gastroenterología. Third-line rescue therapy with levofloxacin after two H.pylori treatment failures. Am J Gastroenterol 2006;101:243-7.
16. Boyanova L, Mentis A, Gubina M, et al. The status of antimicrobial resistance of Helicobacter pylori in eastern Europe. Clin Microbiol Infect 2002;8:388-96.
17. Bakir Ozbey S, Ozakin C, Keskin M. Antibiotic resistance rates of Helicobacter pylori isolates and the comparison of E-test and fluorescent in situ hybridization methods for the detection of clarithromycin resistant strains. Mikrobiyol Bul 2009;43:227-34.
18. Shimoyama T, Kobayashi I, Kato C, Kodama M, Fukuda Y. Comparison of monoclonal antibody-based stool antigen tests to determine the results of Helicobacter pylori eradication therapy. Scand J Gastroenterol 2010;45:1431-4.
19. Kesli R, Gokturk HS, Erbayrak M, Karabagl P, Terzi Y. Comparison of the diagnostic values of the 3 different stool antigen tests for the noninvasive diagnosis of Helicobacter pylori infection. J Investig Med 2010;58:982-6.
20. Huang JQ, Hunt RH. Treatment after failure: the problem of "non-responders". Gut 1999;45(Suppl 1):I40-4.
21. Sánchez JE, Sáenz NG, Rincón MR, Martín IT, Sánchez EG, Martínez MJ. Susceptibility of Helicobacter pylori to mupirocin, oxazolidinones, quinupristin/dalfopristin and new quinolones. J Antimicrob Chemother 2000;46:283-5.
22. Bilardi C, Dulbecco P, Zentilin P, et al. A 10-day levofloxacin-based therapy in patients with resistant Helicobacter pylori infection: a controlled trial. Clin Gastroenterol Hepatol 2004;2:997-1002.
23. Matsumoto Y, Miki I, Aoyama N, et al. Levofloxacin- versus metronidazole-based rescue therapy for H. pylori infection in Japan. Dig Liver Dis 2005;37:821-5.
24. Basu PP, Rayapudi K, Pacana T, Shah NJ, Krishnaswamy N, Flynn M. A randomized study comparing levofloxacin, omeprazole, nitazoxanide, and doxycycline versus triple therapy for the eradication of Helicobacter pylori. Am J Gastroenterol 2011;106:1970-5.
25. Tüzün Y, Bayan K, Yilmaz S, Dursun M, Ozekinci T. The prevalence of primary and secondary Helicobacter pylori resistance to clarithromycin and probable contributing cofactors: data from southeastern Anatolia. Hepatogastroenterology 2008;55:289-93.
26. Demir M, Gokturk HS, Ozturk NA, Arslan H, Serin E, Yilmaz U. Clarithromycin resistance and efficacy of clarithromycin-containing triple eradication therapy for Helicobacter pylori infection in type 2 diabetes mellitus patients. South Med J 2009;102:1116-20.
27. Onder G, Aydin A, Akarca U, Tekin F, Ozutemiz O, Ilter T. High Helicobacter pylori resistance rate to clarithromycin in Turkey. J Clin Gastroenterol 2007;41:747-50.
28. Ozdil K, Calhan T, Sahin A, Senates E, Kahraman R, Yüzbasioglu B, Demirdag H, Demirsoy H, Sökmen MH. Levofloxacin based sequential and triple therapy compared with standard plus probiotic combination for Helicobacter pylori eradication. Hepatogastroenterology 2011;58:1148-52.
29. Gisbert JP, Gisbert JL, Marcos S, Jimenez-Alonso I, Moreno-Otero R, Pajares JM. Empirical rescue therapy after Helicobacter pylori treatment failure: a 10-year single-centre study of 500 patients. Aliment Pharmacol Ther 2008;27:346-54.
30. Kuo CH, Hu HM, Kuo FC, et al. Efficacy of levofloxacin-based rescue therapy for Helicobacter pylori infection after standard triple therapy: a randomized controlled trial. J Antimicrob Chemother 2009;63:1017-24.
31. Nista EC, Candelli M, Cremonini F, et al. Levofloxacin-based triple therapy vs. quadruple therapy in second-line Helicobacter pylori treatment: a randomized trial. Aliment Pharmacol Ther 2003;18:627-33.
32. Ermis F, Akyuz F, Uyanikoglu A, Kurt R, Pinarbasi B, Nazik H, Kaymakoglu S, Mungan Z. Second-line levofloxacin-based triple therapy's efficiency for Helicobacter pylori eradication in patients with peptic ulcer. South Med J 2011;104:579-83.
33. Vakil N, Megraud F. Eradication therapy for Helicobacter pylori. Gastroenterology 2007;133:985-1001.
34. Malfertheiner P, Mégraud F, O'Morain C, Hungin AP, Jones R, Axon A, Graham DY, Tytgat G, European Helicobacter pylori Study Group (EHPSG). Current concepts in the management of Helicobacter pylori infection-the Maastricht 2-2000 Consensus Report. Aliment Pharmacol Ther 2002;16:167-80.
35. Lam SK, Talley NJ. Report of the 1997 Asia Pacific Consensus Conference on the management of Helicobacter pylori infection. J Gastroenterol Hepatol 1998;13:1-12.
36. Gisbert JP, Pérez-Aisa A, Bermejo F, et al. Second-line therapy with levofloxacin after failure of treatment to eradicate Helicobacter pylori infection: time trends in a Spanish Multicenter Study of 1000 patients. J Clin Gastroenterol 2013;47:130-5.